U.S. Markets open in 7 hrs 51 mins

Salarius Pharmaceuticals, Inc. (SLRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.7998-0.0092 (-1.14%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8090
Open0.7900
Bid0.0000 x 3000
Ask0.0000 x 4000
Day's Range0.7900 - 0.8300
52 Week Range0.5550 - 5.3500
Volume48,845
Avg. Volume226,500
Market Cap15.852M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.0750
Earnings DateNov 11, 2020 - Nov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.43
  • GlobeNewswire

    Salarius Pharmaceuticals to Present at BIO Investor Forum Digital

    HOUSTON, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive Officer, David Arthur, will present at the BIO Investor Forum Digital conference taking place Tuesday, October 13, 2020 to Thursday, October 15, 2020. The presentation will be available on demand during the virtual event for all registered attendees. During the presentation, Mr. Arthur will provide an overview of Salarius’ business and highlight recent corporate achievements, as well as anticipated milestones in the clinical programs for seclidemstat. Seclidemstat is a reversible LSD1 inhibitor now the subject of two Phase 1/2 clinical trials for Ewing sarcoma, a rare and deadly pediatric bone cancer, and advanced solid tumors (AST).Details of Salarius’ presentation are as follows:Event:BIO Investor Forum Digital Date: Tuesday, October 13, 2020 to Thursday, October 15, 2020 Time: Available on Demand Registration:https://www.bio.org/events/bio-investor-forum-digital Members of the Salarius management team will be available to participate in one-on-one virtual meetings with investors who are registered to attend the conference. Following the conclusion of the event, a recording of Mr. Arthur’s presentation will be available under “Events & Presentations” in the Investors section of the Company’s website at www.salariuspharma.com.About Salarius PharmaceuticalsSalarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting cancers caused by dysregulated gene expression and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. Salarius’ lead candidate, seclidemstat, is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma, for which it has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit www.salariuspharma.com.Forward-Looking StatementsThis news release includes forward-looking statements within the meaning of the U.S. federal securities laws. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will,” "plan," "could," "may" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.ContactInvestor Relations Tiberend Strategic Advisors, Inc. Maureen McEnroe, CFA/Miriam Miller (212) 375-2664/ 2694  mmcenroe@tiberend.com/mmiller@tiberend.comMedia Relations Tiberend Strategic Advisors, Inc. Johanna Bennett (212) 375-2686  jbennett@tiberend.com

  • GlobeNewswire

    Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to LifeSciencesInvestorForum.com to view presentationsNEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the September 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive discussions focused on the life sciences industry. The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “virtual trade booth”.REGISTER OR LOGIN AT:  https://bit.ly/3m5MTfYSeptember 17th Presenting Companies:Company NameTicker(s) Starpharma Holdings Ltd.OTCQX: SPHRY | ASX: SPL VolitionRx LimitedNYSE AMERICAN: VNRX KemPharm, Inc.OTCQB: KMPH Assure Holdings Corp.OTCQB: ARHH | TSX-V: IOM aTyr Pharma, Inc.Nasdaq: LIFE SWK Holdings, IncNasdaq: SWKH Cardiol Therapeutics Inc.OTCQX: CRTPF | TSX: CRDL XPhyto Therapeutics Corp.OTCQB: XPHYF | CSE: XPHY | FSE: 4XT Nuvo Pharmaceuticals Inc.OTCQX: NRIFF | TSX: NRI Salarius Pharmaceuticals, Inc.Nasdaq: SLRX Willow Biosciences Inc.OTCQB: CANSF | TSX: WLLW Orexo ABOTCQX: ORXOY | Nasdaq STO: ORX Caladrius Biosciences, Inc.Nasdaq: CLBS Kineta, IncPrivate Company Sixth Wave Innovations Inc.OTCQB: ATURF | CSE: SIXW | FSE: AHUH To facilitate investor relations scheduling and for more information about the program, please visit www.lifesciencesinvestorforum.com.About Life Sciences Investor Forum Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.CONTACT Life Sciences Investor Forum John M. Viglotti SVP Corporate Services, Investor Access (212) 220-2221 johnv@lifesciencesinvestorforum.com

  • GlobeNewswire

    Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020

    Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15 AM ET on Thursday, September 17th with the first live webcast at 9:30 AM ET.REGISTER NOW AT: https://bit.ly/3m5MTfYIt is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend the live presentations or ask questions.Agenda and presenting companies:Eastern Time (ET)Company NameTicker(s) 9:30 AMStarpharma Holdings Ltd.OTCQX: SPHRY | ASX: SPL 10:00 AMVolitionRx LimitedNYSE AMERICAN: VNRX 10:30 AMKemPharm, Inc.OTCQB: KMPH 11:00 AMAssure Holdings Corp.OTCQB: ARHH | TSX-V: IOM 11:30 AMaTyr Pharma, Inc.Nasdaq: LIFE 12:00 PMSWK Holdings, IncNasdaq: SWKH 12:30 PMCardiol Therapeutics Inc.OTCQX: CRTPF | TSX: CRDL 1:00 PMXPhyto Therapeutics Corp.OTCQB: XPHYF | CSE: XPHY | FSE: 4XT 1:30 PMNuvo Pharmaceuticals Inc.OTCQX: NRIFF | TSX: NRI 2:00 PMSalarius Pharmaceuticals, Inc.Nasdaq: SLRX 2:30 PMWillow Biosciences Inc.OTCQB: CANSF | TSX: WLLW 3:00 PMOrexo ABOTCQX: ORXOY | Nasdaq STO: ORX 3:30 PMCaladrius Biosciences, Inc.Nasdaq: CLBS 4:00 PMKineta, IncPrivate Company 4:30 PMSixth Wave Innovations Inc.OTCQB: ATURF | CSE: SIXW | FSE: AHUH To facilitate investor relations scheduling and for more information about the program, please visit www.lifesciencesinvestorforum.com.About Life Sciences Investor Forum
 Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network. CONTACT: CONTACT Life Sciences Investor Forum John M. Viglotti SVP Corporate Services, Investor Access (212) 220-2221 johnv@lifesciencesinvestorforum.com